|
US11982672B2
(en)
|
2014-03-05 |
2024-05-14 |
Autolus Limited |
Methods
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
CN108395482B
(zh)
|
2017-02-08 |
2021-02-05 |
西比曼生物科技（香港）有限公司 |
一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
|
|
CN110944651A
(zh)
|
2017-02-08 |
2020-03-31 |
蜻蜓疗法股份有限公司 |
用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
|
|
EP4273258A3
(en)
|
2017-02-20 |
2024-01-17 |
Dragonfly Therapeutics, Inc. |
Proteins binding her2, nkg2d and cd16
|
|
JP2020530554A
(ja)
|
2017-07-20 |
2020-10-22 |
シートムエックス セラピューティクス，インコーポレイテッド |
活性化抗体の特性を定性的および／または定量的に分析する方法およびその使用
|
|
KR102172092B1
(ko)
|
2017-09-19 |
2020-10-30 |
주식회사 엘지화학 |
열가소성 수지 조성물, 이의 제조방법 및 성형품
|
|
CA3078969A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
WO2019079009A1
(en)
*
|
2017-10-20 |
2019-04-25 |
Nantbio, Inc. |
METHODS OF MONITORING IMMUNOTHERAPY OF BLADDER CANCER
|
|
CA3090244A1
(en)
|
2018-02-08 |
2019-08-15 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting the nkg2d receptor
|
|
MX2020008333A
(es)
|
2018-02-08 |
2020-09-21 |
Dragonfly Therapeutics Inc |
Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
|
|
EP3806870A4
(en)
*
|
2018-02-13 |
2021-12-22 |
Chimera Bioengineering, Inc. |
COORDINATION OF GENE EXPRESSION USING RNA DESSTABILIZATION ELEMENTS
|
|
CN112119093A
(zh)
|
2018-02-20 |
2020-12-22 |
蜻蜓治疗公司 |
结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
|
|
US20220025037A1
(en)
*
|
2018-04-03 |
2022-01-27 |
Dragonfly Therapeutics, Inc. |
Antibody variable domains targeting dll3, and use thereof
|
|
CR20200539A
(es)
*
|
2018-04-10 |
2021-07-01 |
Kite Pharma Inc |
Receptores quiméricos de dll3 y métodos para su uso
|
|
TW202010757A
(zh)
|
2018-04-11 |
2020-03-16 |
美商英伊布里克斯公司 |
具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途
|
|
AU2019267349B2
(en)
*
|
2018-05-08 |
2025-06-05 |
Phanes Therapeutics, Inc. |
Anti-DLL3 antibodies and uses thereof
|
|
MX2020012217A
(es)
|
2018-05-14 |
2021-03-02 |
Harpoon Therapeutics Inc |
Porción de unión para activación condicional de moléculas de inmunoglobulina.
|
|
WO2020023553A1
(en)
|
2018-07-24 |
2020-01-30 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
CA3108427A1
(en)
|
2018-08-08 |
2020-02-13 |
Dragonfly Therapeutics, Inc. |
Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
|
|
CN113164570B
(zh)
|
2018-08-08 |
2024-05-14 |
蜻蜓疗法股份有限公司 |
结合nkg2d、cd16和肿瘤相关抗原的蛋白质
|
|
EA202091888A1
(ru)
|
2018-08-08 |
2020-10-23 |
Драгонфлай Терапьютикс, Инк. |
Вариабельные домены антител, нацеленные на рецептор nkg2d
|
|
EP3850088A4
(en)
|
2018-09-07 |
2023-07-19 |
Beam Therapeutics, Inc. |
Compositions and methods for improving base editing
|
|
KR20210055733A
(ko)
|
2018-09-07 |
2021-05-17 |
빔 테라퓨틱스, 인크. |
핵염기 편집 시스템을 전달하기 위한 조성물 및 방법
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
JP7611820B2
(ja)
*
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
EP3892333A4
(en)
*
|
2018-12-07 |
2022-11-30 |
CRAGE medical Co., Limited |
ANTI-TUMOR POLYIMMUNOTHERAPY
|
|
JP7646552B2
(ja)
|
2019-01-31 |
2025-03-17 |
ビーム セラピューティクス インク． |
低減された非標的脱アミノ化を有する核酸塩基エディターおよび核酸塩基エディターの特徴づけのためのアッセイ
|
|
WO2020168135A1
(en)
|
2019-02-13 |
2020-08-20 |
Beam Therapeutics Inc. |
Compositions and methods for treating alpha-1 antitrypsin deficiency
|
|
US12600971B2
(en)
|
2019-02-13 |
2026-04-14 |
Beam Therapeutics Inc. |
Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
|
|
MX2021010441A
(es)
*
|
2019-03-01 |
2021-09-21 |
Allogene Therapeutics Inc |
Receptores antigenicos quimericos y agentes de union dirigidos a dll3.
|
|
US20220145397A1
(en)
*
|
2019-03-08 |
2022-05-12 |
Oncolab Diagnostics Gmbh |
Cancer diagnosis and prognosis
|
|
MX2021012336A
(es)
*
|
2019-04-08 |
2021-11-12 |
Phanes Therapeutics Inc |
Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.
|
|
WO2020232303A1
(en)
|
2019-05-14 |
2020-11-19 |
Harpoon Therapeutics, Inc. |
EpCAM BINDING PROTEINS AND METHODS OF USE
|
|
EP4527466A3
(en)
*
|
2019-07-17 |
2025-06-18 |
Legend Biotech Ireland Limited |
Anti-dll3 chimeric antigen receptors and uses thereof
|
|
US20210046117A1
(en)
*
|
2019-08-18 |
2021-02-18 |
Chimera Bioengineering, Inc. |
Combination Therapy with Gold Controlled Transgenes
|
|
US12594301B2
(en)
|
2019-09-27 |
2026-04-07 |
Beam Therapeutics Inc. |
Compositions and methods for treatment of liquid cancers
|
|
EP4097129A1
(en)
|
2020-01-29 |
2022-12-07 |
Inhibrx, Inc. |
Cd28 single domain antibodies and multivalent and multispecific constructs thereof
|
|
US11976133B2
(en)
*
|
2020-01-31 |
2024-05-07 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
US12486331B2
(en)
|
2020-01-31 |
2025-12-02 |
Gensun Biopharma Inc. |
Bispecific T cell engagers
|
|
WO2021180215A1
(en)
|
2020-03-12 |
2021-09-16 |
Nanjing Legend Biotech Co., Ltd. |
Glypican-2-binding moieties, chimeric antigen receptors and uses thereof
|
|
CN113402612A
(zh)
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
CN113444172A
(zh)
*
|
2020-03-25 |
2021-09-28 |
兴盟生物医药(苏州)有限公司 |
金黄色葡萄球菌α-毒素特异性抗体及其应用
|
|
AU2021268340A1
(en)
|
2020-05-06 |
2022-12-08 |
Dragonfly Therapeutics, Inc. |
Proteins binding NKG2D, CD16 and CLEC12A
|
|
AU2021347359A1
(en)
|
2020-09-25 |
2023-05-18 |
Beam Therapeutics Inc. |
Fratricide resistant modified immune cells and methods of using the same
|
|
JP2023548590A
(ja)
*
|
2020-11-06 |
2023-11-17 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
小細胞肺がんの分類と治療のための方法およびシステム
|
|
EP4301774A4
(en)
|
2021-03-03 |
2025-08-13 |
Dragonfly Therapeutics Inc |
METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
|
|
US20240150456A1
(en)
*
|
2021-04-02 |
2024-05-09 |
Nanjing Legend Biotech Co., Ltd. |
Engineered immune cells and uses thereof
|
|
CA3230627A1
(en)
*
|
2021-09-02 |
2023-03-09 |
Memorial Sloan-Kettering Cancer Center |
Antigen recognizing receptors targeting dll3 and uses thereof
|
|
PE20260290A1
(es)
|
2023-03-31 |
2026-02-10 |
Abelzeta Inc |
Receptores de antigeno quimericos biespecificos dirigidos a cd20 y bcma
|
|
CN117169518B
(zh)
*
|
2023-11-03 |
2024-01-19 |
赛德特(北京)生物工程有限公司 |
T淋巴细胞制剂中的cd3抗体残留物的检测方法和试剂盒
|
|
WO2025212519A1
(en)
*
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2026059931A2
(en)
*
|
2024-09-11 |
2026-03-19 |
Telix Targeting Technologies, Inc. |
Dll3 antigen binding constructs
|